Bayer Onyx Nexavar Agreement

Categoría/s:

These forward-looking statements include, but are not limited to, statements about the agreements entered into by Bayer and Onyx regarding Nexavar and Regorafenib, the commercialization efforts or commercial potential of Nexavar and Regorafenib, and the clinical development, safety and authorization processes of Nexavar, Regorafénib and Carfilzomib. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those expected, including risks related to Nexavar being Onyx`s only authorized product; Regorafenib is not authorized, may never obtain marketing authorization and can never generate royalties for Onyx; competition; errors or delays in clinical trials or in the marketing authorisation procedure; dependence on Onyx`s cooperation with Bayer; market acceptance and product acceptance rate; pressure on drug prices and reimbursement; and serious adverse reactions associated with nexavar, regorafenib or carfilzomib. All statements contained in this press release, which are not statements of historical fact, may be considered forward-looking statements. For a more detailed description of these factors, refer to Onyx`s Annual Report on Form 10-K for the year ended December 31, 2010, submitted to the Securities and Exchange Commission under the heading «Risk Factors,» and Onyx`s subsequent quarterly reports on Form 10-Q. Readers are cautioned not to place undue reliance on these forward-looking statements, which apply only at the time of this press release. Onyx undertakes no commitment to publicly update any forward-looking statements to reflect new information, events or circumstances after the date of this press release, except as required by law. Onyx and Bayer entered into their initial partnership, a joint venture, in 1994 to develop and commercialize sorafenib as part of a class of cancer therapies known as kinase inhibitors. Onyx had recently argued, in a lawsuit, that the next drug, regorafenib, also fell under the terms of that agreement.